Loading organizations...
Batu Biologics is a preclinical biopharmaceutical company based in San Diego, California, that develops allogeneic cell therapies and immuno-oncology treatments for solid tumors. The organization primarily focuses on advancing ValloVax, an investigational cancer vaccine designed to stimulate the patient's immune system to target and destroy the blood vessels feeding solid tumors. To support its research and development pipeline, the enterprise has raised over $1.5 million in early-stage funding through venture capital, angel investments, and equity crowdfunding campaigns on platforms like MicroVentures and Indiegogo. The firm previously secured clearance from the FDA for its Investigational New Drug application to initiate Phase I clinical trials targeting non-small cell lung cancer and other indications. Operating with a business model geared toward eventual commercialization or licensing, Batu Biologics was founded in 2013 by Samuel Wagner, Dr. Thomas Ichim, and Amit Patel.
Batu Biologics has raised $2.4M across 3 funding rounds.
Batu Biologics has raised $2.4M in total across 3 funding rounds.
Batu Biologics has raised $2.4M in total across 3 funding rounds.
Batu Biologics's investors include EquityNet, Indiegogo.
Batu Biologics has raised $2.4M across 3 funding rounds. Most recently, it raised $1.3M Other Equity in December 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 25, 2017 | $1.3M Venture Round | EquityNet | — | Announced |
| Jun 22, 2015 | $1M Seed | — | — | Announced |
| Jun 18, 2014 | $100K Venture Round | Indiegogo | — | Announced |
